TITLE:
Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.

CONDITION:
Sarcoma, Kaposi

INTERVENTION:
Doxorubicin hydrochloride (liposomal)

SUMMARY:

      To provide Stealth liposomal doxorubicin hydrochloride ( DOX-SL ) as a therapy for Kaposi's
      sarcoma patients who have no remaining treatment options other than DOX-SL or patients who
      have been participating in another DOX-SL protocol and for whom continuation in DOX-SL is
      medically indicated. Also, to evaluate the safety and efficacy of DOX-SL in patients with
      Kaposi's sarcoma who have previously received systemic chemotherapy with or without an
      anthracycline.
    

DETAILED DESCRIPTION:

      Patients receive DOX-SL every 3 weeks for up to 20 cycles.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have:

          -  AIDS-related Kaposi's sarcoma that requires systemic chemotherapy.

          -  EITHER a medical indication for continuation of DOX-SL following treatment on another
             DOX-SL protocol, OR no remaining treatment options other than DOX-SL.

        Prior Medication:

        Allowed:

          -  Prior anthracyclines.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Cardiac ejection fraction < 50 percent or clinically significant cardiac disease.

          -  Eligibility for a Liposomal Technology comparative protocol.

        Concurrent Medication:

        Excluded:

          -  Other cytotoxic chemotherapy.

        Patients with the following prior condition are excluded:

        History of idiosyncratic or allergic reaction to anthracyclines.

        Prior Medication:

        Excluded:

          -  Chemotherapy within the past 3 weeks.
      
